Literature DB >> 11600374

Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.

C S Gavigan1, S G Machado, J P Dalton, A Bell.   

Abstract

The pathway of hemoglobin degradation by erythrocytic stages of the human malarial parasite Plasmodium falciparum involves initial cleavages of globin chains, catalyzed by several endoproteases, followed by liberation of amino acids from the resulting peptides, probably by aminopeptidases. This pathway is considered a promising chemotherapeutic target, especially in view of the antimalarial synergy observed between inhibitors of aspartyl and cysteine endoproteases. We have applied response-surface modelling to assess antimalarial interactions between endoprotease and aminopeptidase inhibitors using cultured P. falciparum parasites. The synergies observed were consistent with a combined role of endoproteases and aminopeptidases in hemoglobin catabolism in this organism. As synergies between antimicrobial agents are often inferred without proper statistical analysis, the model used may be widely applied in studies of antimicrobial drug interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600374      PMCID: PMC90800          DOI: 10.1128/AAC.45.11.3175-3181.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

Review 2.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum.

Authors:  S E Francis; D J Sullivan; D E Goldberg
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

Review 3.  Statistical analysis of drug-drug and site-site interactions with isobolograms.

Authors:  R J Tallarida; F Porreca; A Cowan
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

4.  A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments.

Authors:  S G Machado; G A Robinson
Journal:  Stat Med       Date:  1994-11-30       Impact factor: 2.373

Review 5.  Malaria vaccines: multiple targets.

Authors:  R S Nussenzweig; C A Long
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

6.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

7.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

8.  A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum.

Authors:  P J Rosenthal; J H McKerrow; M Aikawa; H Nagasawa; J H Leech
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

9.  Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production.

Authors:  K A Kolakovich; I Y Gluzman; K L Duffin; D E Goldberg
Journal:  Mol Biochem Parasitol       Date:  1997-08       Impact factor: 1.759

10.  Toxicological studies on bestatin. I. Acute toxicity test in mice, rats and dogs.

Authors:  T Sakakibara; K Ito; Y Irie; T Hagiwara; Y Sakai; M Hayashi; H Kishi; M Sakamoto; M Suzuki; Y Irie
Journal:  Jpn J Antibiot       Date:  1983-11
View more
  4 in total

1.  Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase.

Authors:  Sheena McGowan; Corrine J Porter; Jonathan Lowther; Colin M Stack; Sarah J Golding; Tina S Skinner-Adams; Katharine R Trenholme; Franka Teuscher; Sheila M Donnelly; Jolanta Grembecka; Artur Mucha; Pawel Kafarski; Ross Degori; Ashley M Buckle; Donald L Gardiner; James C Whisstock; John P Dalton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

2.  The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria.

Authors:  Tina S Skinner-Adams; Christopher L Peatey; Karen Anderson; Katharine R Trenholme; David Krige; Christopher L Brown; Colin Stack; Desire M M Nsangou; Rency T Mathews; Karine Thivierge; John P Dalton; Donald L Gardiner
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases.

Authors:  Michael B Harbut; Geetha Velmourougane; Seema Dalal; Gilana Reiss; James C Whisstock; Ozlem Onder; Dustin Brisson; Sheena McGowan; Michael Klemba; Doron C Greenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

4.  Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.

Authors:  Eithne Cunningham; Marcin Drag; Pawel Kafarski; Angus Bell
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.